A Phase I Study of XH-S002 in Healthy Volunteers - Trial NCT06204419
Access comprehensive clinical trial information for NCT06204419 through Pure Global AI's free database. This Phase 1 trial is sponsored by S-Infinity Pharmaceuticals Co., Ltd and is currently Recruiting. The study focuses on Healthy Adults. Target enrollment is 86 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
S-Infinity Pharmaceuticals Co., Ltd
Timeline & Enrollment
Phase 1
Dec 26, 2023
Oct 01, 2024
Primary Outcome
To access the safety and tolerability of single ascending dosed of XH-S002 in healthy adults.,To access the safety and tolerability of multiple ascending dosed of XH-S002 in healthy adults.
Summary
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of
 XH-S002 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending
 dose) studies. In addition, this study evaluates the food effects of XH-S002.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06204419
Non-Device Trial